J.D. BITRAN, M.D.; D.L. SWEET, M.D.; J. VARDIMAN, M.D.; H.M. GOLOMB, M.D.; J.E. ULTMANN, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Advanced diffuse histiocytic lymphoma is curable when treated with combination chemotherapy (1). There is a small risk (13%) of recurrent lymphoma within the first 36 months in patients with a complete response to chemotherapy. Usually, reinstitution of the initial chemotherapeutic regimen may control recurrent lymphoma. Although patients with nodular lymphoma (follicular center lymphoma) may show conversion to a diffuse histologic form (3), conversion of diffuse histiocytic lymphoma to a nodular histologic form has not been reported.
In 1980, we reported the results of treatment with the cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (COMLA) regimen in
BITRAN J, SWEET D, VARDIMAN J, GOLOMB H, ULTMANN J. Histiocytic Lymphoma: Response to Chemotherapy. Ann Intern Med. ;97:617–618. doi: 10.7326/0003-4819-97-4-617_3
Download citation file:
Published: Ann Intern Med. 1982;97(4):617-618.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use